Federated Hermes
RVNC

Federated Hermes’s Revance Therapeutics, Inc. RVNC Stock Holding History

Federated Hermes’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-9
Closed -$47 – 2210
2024
Q3 		$47 Sell
9
-2,237,496
-100% -$11.1M ﹤0.01% 2025
2024
Q2 		$5.75M Buy
2,237,505
+672,803
+43% +$2.3M 0.01% 682
2024
Q1 		$7.7M Buy
1,564,702
+1,482,525
+1,804% +$8.78M 0.02% 623
2023
Q4 		$722K Buy
82,177
+43,389
+112% +$355K ﹤0.01% 1241
2023
Q3 		$445K Buy
38,788
+32,345
+502% +$622K ﹤0.01% 1377
2023
Q2 		$163K Buy
+6,443
New +$201K ﹤0.01% 1577
2023
Q1 		– Sell
-36,302
Closed -$670K – 2290
2022
Q4 		$670K Sell
36,302
-59,844
-62% -$1.37M ﹤0.01% 1264
2022
Q3 		$2.6M Sell
96,146
-25,254
-21% -$512K 0.01% 844
2022
Q2 		$1.68M Buy
+121,400
New +$1.87M ﹤0.01% 978
2018
Q4 		– Sell
-83,810
Closed -$2.08M – 2332
2018
Q3 		$2.08M Buy
83,810
+3,680
+5% +$100K ﹤0.01% 1073
2018
Q2 		$2.2M Buy
80,130
+21,600
+37% +$649K 0.01% 972
2018
Q1 		$1.8M Buy
58,530
+20,245
+53% +$651K 0.01% 1006
2017
Q4 		$1.37M Sell
38,285
-12,000
-24% -$345K ﹤0.01% 1103
2017
Q3 		$1.39M Buy
50,285
+30,285
+151% +$734K ﹤0.01% 1086
2017
Q2 		$528K Sell
20,000
-51
-0.3% -$1.14K ﹤0.01% 1371
2017
Q1 		$417K Buy
20,051
+51
+0.3% +$1.05K ﹤0.01% 1372
2016
Q4 		$414K Hold
20,000
– – ﹤0.01% 1362
2016
Q3 		$324K Hold
20,000
– – ﹤0.01% 1396
2016
Q2 		$272K Hold
20,000
– – ﹤0.01% 1422
2016
Q1 		$349K Hold
20,000
– – ﹤0.01% 1377
2015
Q4 		$683K Buy
+20,000
New +$693K ﹤0.01% 1205
2014
Q2 		– Sell
-49,490
Closed -$1.56M – 2005
2014
Q1 		$1.56M Buy
+49,490
New +$1.55M 0.01% 1038

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Federated Hermes's RVNC Position: Q4 2024 in Review

Federated Hermes sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 9 shares — an estimated $47 sold.

Federated Hermes first reported a position in RVNC in Q1 2014 and held it in 22 quarters. The position peaked at $7.7M in Q1 2024. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Federated Hermes reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Federated Hermes sold 9 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $47.
  • Federated Hermes first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 22 quarters.
  • Federated Hermes's Revance Therapeutics, Inc. position peaked at $7.7M in Q1 2024.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Federated Hermes's 13F filing for Q4 2024, filed 13 Feb 2025.